The younger, seemingly fit population is increasingly being afflicted with lean fatty liver disease due to hidden visceral ...

If inflammation persists, NASH can progress to fibrosis marked by scarring of liver tissue. Advanced fibrosis may eventually ...

Dr. Saurabh Sethi notes that most people believe sugar affects weight. However, it can strongly influence your liver.

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease, and if it is accurately predicted, severe fibrosis and cirrhosis can be prevented. While liver biopsies, the ...

Mitochondrial respiratory complexes (Complexes I–V) and their assembly into respiratory supercomplexes (SCs) are fundamental to liver bioenergetics, redox homeostasis, and metabolic adaptability.

Between 2010 and 2021, India recorded a 13.2 percent increase in non-alcoholic fatty liver disease (NAFLD) cases. According ...

A1C, LDL, HDL… the number of medical abbreviations you might see on your patient portal is enough to make you think your ...

One Viking Therapeutics insider sold 57,661 shares of the company for about $1.9 million on Monday. The sale represented 23.29% of Zante's direct holdings, which fell from 247,552 to 189,891 shares, ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...

Experienced Industry Leader with More than Two Decades of Global Commercialization and Marketing Expertise SAN DIEGO, Jan. 7, 2026 /PRNewswire/ -- Viking Therapeutics ...